Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Reprod Sci ; 31(1): 1-16, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37500976

RESUMEN

Autoimmune primary ovarian insufficiency (POI) is a devastating disease with limited clinical guidance. The objective of this systematic review was to identify treatments for autoimmune POI and analyze their efficacy. A comprehensive search of CINAHL, Cochrane, Embase, PubMed, Scopus, and Web of Science was performed from inception to April 2022. English language publications that evaluated women with autoimmune POI after a documented intervention were included. Animal models of autoimmune POI were also included. Risk of bias was assessed with the SYRCLE's risk of bias tool for animal studies or the NIH Quality Assessment Tool for Case Series as appropriate. Twenty-eight studies were included in this review, with 11 RCTs, 15 case reports, and 2 case series. Seventeen studies were in humans, and 11 were in animal models. No completed RCTs, cohort studies, or case-control studies were identified in humans. In observational human studies, corticosteroids were effective in select patients. In many case reports, adequate treatment of comorbid autoimmune conditions resulted in return of menses, hormonal normalization, or spontaneous pregnancy. In terms of assisted reproductive technologies, there was case report evidence for both in vitro fertilization (IVF) and in vitro maturation (IVM) in women wishing to conceive with their own oocytes. Ovulation induction, IVF, and IVM resulted in a total of 15 pregnancies and 14 live births. In animal models, there was additional evidence for stem cell therapies and treatments used in traditional Chinese medicine, although this research may not be generalizable to humans. Furthermore, litter size was not evaluated in any of the animal studies. Additional research is needed to establish the efficacy of current treatments for autoimmune POI with a controlled experimental design and larger sample size. Additionally, there is a critical need to develop novel therapies for this condition, as understanding of its pathophysiology and  available tools to modulate the immune response have progressed.


Asunto(s)
Infertilidad Femenina , Ooforitis , Poliendocrinopatías Autoinmunes , Animales , Femenino , Humanos , Embarazo , Fertilización In Vitro/métodos , Infertilidad Femenina/etiología , Nacimiento Vivo , Ooforitis/terapia , Poliendocrinopatías Autoinmunes/terapia , Índice de Embarazo , Técnicas Reproductivas Asistidas/efectos adversos
2.
Medicine (Baltimore) ; 99(18): e20000, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32358377

RESUMEN

RATIONALE: Autoimmune polyendocrine syndrome type 1 (APS-1), also referred as the autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy (APECED), is a rare autosomal inherited disease predominantly among Caucasians from Northern Europe. This syndrome is very rare in East Asian population. PATIENTS CONCERNS: Here, we describe a case of a 15-year-old Chinese boy admitted due to a 1-month history of intermittent fatigue, nausea, vomiting, and diarrhea. His symptom became worse accompanied with chest tightness 4 days before admission. On physical examination, his temperature was 38.5°C, blood pressure was 75/38 mm Hg, and pulse was 98/min. He was a thin boy with mild hyperpigmentation and xanthochromia. DIAGNOSIS: After abdominal computed technology and laboratory tests, his diagnosis was APS-1 accompanied with adrenal crisis. Further investigation on whole-exome sequencing revealed a novel homozygous mutation c.47C>G (p.T16R) in exon 1 in the autoimmune regulator (AIRE) gene. INTERVENTIONS: This patient underwent replacement therapy of glucocorticoids, corticosteroid, and levothyroxine, as well as calcium and calcitriol supplementation. OUTCOMES: He continues to do well 4 years after his hospitalization. During his last follow-up, he had serum thyroid-stimulating hormone level of 3.07 µIU/mL, free triiodothyronine level of 1.92 pg/mL, and free thyroxine level of 13.95 pg/mL. His serum cortisol and ACTH (8 a.m.) levels were 28.53 µg/dL and 69.48 pg/mL, respectively. LESSONS: APS-1 is very rare in East Asians and the variable clinical presentations of the disease make the initial diagnosis especially difficult. Autoimmune thyroiditis, type 1 diabetes mellitus, and hepatitis were the three most frequent minor components of APS-1 in East Asian patients with age of onset in late teens and 20s. Sequence analysis of AIRE gene is necessary to verify its diagnostic efficacy in association with clinical findings.


Asunto(s)
Poliendocrinopatías Autoinmunes/genética , Factores de Transcripción/genética , Adolescente , China , Humanos , Masculino , Poliendocrinopatías Autoinmunes/diagnóstico , Poliendocrinopatías Autoinmunes/terapia , Proteína AIRE
3.
Gut Liver ; 8(3): 324-8, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24827631

RESUMEN

To evaluate the effects of glutamine-supplemented parenteral nutrition (PN) and probiotics in adult autoimmune enteropathy (AIE) patients. Four adult AIE patients were identified from April 2006 to January 2012. Clinical and nutritional data were obtained from the patients' medical records. Glutamine-supplemented PN started immediately when the AIE diagnosis was confirmed. The total PN duration was 351 days. According to the PN prescription, the average caloric intake ranged from 20 to 25 kcal/kg/day, and the protein intake ranged from 1.2 to 1.5 g/kg/day. Alanyl-glutamine (20 g/day) was administered to AIE patients for 4 weeks followed by a 2-week break, and this treatment schedule was repeated when PN lasted for more than 6 weeks. Body weight gain and an increased serum albumin level were achieved after PN, and defecation frequency and quality also improved. Each patient received oral supplements, 250 mL of Ensure and two probiotics capsules (each capsule containing 0.5×108 colonies) three times a day when enteral nutrition started. Three AIE patients were successfully weaned off PN, and one patient died of pneumonia. Glutamine-supplemented PN and probiotics show promise in managing patients with AIE and related malnutrition.


Asunto(s)
Glutamina/administración & dosificación , Nutrición Parenteral/métodos , Poliendocrinopatías Autoinmunes/terapia , Probióticos/administración & dosificación , Adulto , Bifidobacterium , Enterococcus faecalis , Femenino , Humanos , Lactobacillus acidophilus , Tiempo de Internación , Masculino , Desnutrición/terapia , Adulto Joven
4.
Gut and Liver ; : 324-328, 2014.
Artículo en Inglés | WPRIM | ID: wpr-163233

RESUMEN

To evaluate the effects of glutamine-supplemented parenteral nutrition (PN) and probiotics in adult autoimmune enteropathy (AIE) patients. Four adult AIE patients were identified from April 2006 to January 2012. Clinical and nutritional data were obtained from the patients' medical records. Glutamine-supplemented PN started immediately when the AIE diagnosis was confirmed. The total PN duration was 351 days. According to the PN prescription, the average caloric intake ranged from 20 to 25 kcal/kg/day, and the protein intake ranged from 1.2 to 1.5 g/kg/day. Alanyl-glutamine (20 g/day) was administered to AIE patients for 4 weeks followed by a 2-week break, and this treatment schedule was repeated when PN lasted for more than 6 weeks. Body weight gain and an increased serum albumin level were achieved after PN, and defecation frequency and quality also improved. Each patient received oral supplements, 250 mL of Ensure and two probiotics capsules (each capsule containing 0.5x10(8) colonies) three times a day when enteral nutrition started. Three AIE patients were successfully weaned off PN, and one patient died of pneumonia. Glutamine-supplemented PN and probiotics show promise in managing patients with AIE and related malnutrition.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Adulto Joven , Bifidobacterium , Enterococcus faecalis , Glutamina/administración & dosificación , Lactobacillus acidophilus , Tiempo de Internación , Desnutrición/terapia , Nutrición Parenteral/métodos , Poliendocrinopatías Autoinmunes/terapia , Probióticos/administración & dosificación
5.
BMJ Case Rep ; 20132013 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-23370953

RESUMEN

We present a case of an 18-year-old Caucasian man with a rare autosomal recessive disorder called autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED). This patient had manifestations of all clinical components of this multisystemic disease which included intestinal failure secondary to autoimmune enteropathy. We present a unique multidisciplinary management for this genetic condition. Although patients with APECED do not always have all the disease components (a total of eight exist), the majority have at least 3-5 components. This excludes the psychosexual implications which are often ignored. This case highlights the importance of (1) management of APECED in a multidisciplinary nature that includes a gastroenterologist, immunologist, endocrinologist, dietitians, etc and the (2) management of intestinal failure component of APECED is best suited in a specialist intestinal failure unit where expertise is available for complex malabsorption disorders.


Asunto(s)
Poliendocrinopatías Autoinmunes/terapia , Adolescente , Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Candidiasis Mucocutánea Crónica/etiología , Candidiasis Bucal/etiología , Colonoscopía , Enfermedades Duodenales/etiología , Enfermedades Duodenales/patología , Duodeno/patología , Humanos , Inmunosupresores/uso terapéutico , Masculino , Desnutrición/etiología , Terapia Nutricional , Grupo de Atención al Paciente , Poliendocrinopatías Autoinmunes/complicaciones , Poliendocrinopatías Autoinmunes/diagnóstico , Rituximab
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA